H.C. Wainwright lowered the firm’s price target on Century Therapeutics to $9 from $11 and keeps a Buy rating on the shares. The analyst updated the company’s model post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics initiated with a Buy at Rodman & Renshaw
- Century Therapeutics Provides Investor Meeting Slide Update
- Century Therapeutics reports Q2 EPS (38c), consensus (46c)
- Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics files to sell 7.87M shares of common stock for holders
Questions or Comments about the article? Write to editor@tipranks.com